Royalty Pharma sells 20% of its royalty interest in Ibrutinib

Royalty Pharma says that pursuant to its collaboration with Aisling Capital and Clarus Ventures, it has sold the two companies around 20% of its royalty interest in Ibrutinib it recently acquired from Quest Diagnostics (DGX -0.2%).

In payment, its will receive a pro rata percentage of the $485M it paid to Quest for the royalty.

Pharmacyclics (PCYC +0.1%) and Johnson & Johnson (JNJ +0.3%) subsidiary Janssen Pharmaceuticals filed Ibrutinib with the FDA in July 2013 for the treatment of lymphoma and relapsed/refractory chronic lymphocytic leukemia, and currently has received three of the eight Breakthrough Therapy Designations granted by the FDA to date in oncology.

From other sites
Comments (2)
  • Ty Ritterr
    , contributor
    Comments (40) | Send Message
    While following PCYC and progress of Ibrutinib in its pipeline for months, I remained, and still remain, clueless as to the interest of Royalty Pharma, Aisling Capital, Clarus Ventures and Quest Diagnostics.


    The plot thickens (: > (


    Meantime, OPK and PCYC have really been a boon to my portfolio YTD.
    12 Aug 2013, 11:15 PM Reply Like
  • Ty Ritterr
    , contributor
    Comments (40) | Send Message
    I'm just a newbie. I've only been investing in stocks for about thirty years.


    Can't say I've learned something every day. But maybe every quarter.


    My annual goal is which is the lesser of 30%, or beating the DOW by 15%.


    People don't need to know any more than that about me.
    12 Aug 2013, 11:20 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs